Genprex Shares Fall 3.8% as TUSC2 Gene‑Therapy Update Spurs Investor Uncertainty
Genprex’s stock dips 3.8% after a new study links its TUSC2 gene target to brain aging, showing deeper decline for investors.
2 minutes to read
GENPREX INC
Genprex (GNPX) Climbs 3.4% to $2.05 Amid Strong 24‑Hour Trading Volume
Genprex (GNPX) stock rose 3.4% to $2.05, trading $498k amid a 38.8% decline. Learn key biotech insights, market cap, and related tickers.
One minute to read